China Meheco Group (SHA:600056) said eight of its drugs were proposed to be selected for the twelfth round of China's National Centralized Drug Procurement, according to a Shanghai bourse filing on Tuesday.
The drugs, which were all produced by the company's subsidiaries, are betahistine hydrochloride tablets, vonoprazan fumarate tablets, vitamin B6 injection, sacubitril/valsartan sodium tablets, isavuconazole sulfate for injection, edoxaban tosylate tablets, carbazochrome sodium sulfonate injection and valacyclovir hydrochloride tablets.